Monoclonal Antibodies Market
Monoclonal Antibodies Market Analysis by Murine, Chimeric, Humanized, and Human Source for Cancer, Autoimmune Diseases, Inflammatory Diseases, and Infectious Diseases from 2023 to 2033
Analysis of Monoclonal Antibodies Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Monoclonal Antibodies Market Outlook (2023 to 2033)
Newly released data by Fact.MR, a market research and competitive intelligence provider, reveals that the global monoclonal antibodies market size is valued at US$ 228.99 billion in 2023 and is forecasted to reach US$ 692.39 billion, expanding swiftly at a CAGR of 11.7% through 2033.
The market represents a healthcare revolution, providing tailored and precise therapeutic options for a wide range of diseases. Monoclonal antibodies (mAbs), which are biologically created molecules that attach to specific antigens or proteins, have emerged as a critical component of precision medicine. Because of their adaptability, personalization, and use in a variety of therapeutic areas, they are invaluable tools for enhancing patient care.
Rising prevalence of chronic diseases, especially cancer and autoimmune disorders, is driving the demand for monoclonal antibodies. These biologics provide extremely effective monoclonal antibody treatment alternatives, which contribute to market growth.
Pharmaceutical and biotechnology businesses are investing considerably in research and development in the monoclonal antibodies market to create monoclonal antibodies with improved therapeutic efficacy. The discovery and development of monoclonal antibodies are being driven by strategic cooperation between pharmaceutical corporations, academic institutions, and research groups. As healthcare professionals and patients become more aware of the benefits of monoclonal antibodies, there is a greater demand for these medicines.
Key Market Growth Drivers
- Monoclonal antibodies are extremely adaptable. They can be tailored to target a specific protein or antigen, making them suitable for a wide range of therapeutic applications.
- Monoclonal antibodies are the pinnacle of personalized medicine. They allow healthcare practitioners to tailor medicines to patient’s specific genetic and molecular profiles, resulting in more effective and tailored therapeutic outcomes.
- Monoclonal antibodies can target specific cancer cells while protecting healthy cells in oncology. They aid in the regulation of an excessive immune response in autoimmune disorders. Their applications also include infectious diseases.
- Biotechnology advances, such as genome sequencing and protein engineering, have aided in the creation of innovative monoclonal antibody therapeutics. This advancement is fueling the discovery of new therapeutic targets and expanding patient treatment options.
- Recognizing the potential of monoclonal antibodies to meet unmet medical needs, regulatory agencies have expedited the approval procedure for these biologics. This has given additional push to research and development in this area.
- Monoclonal antibodies provide great therapy efficacy with low adverse effects because of their tailored strategy.
Monoclonal antibodies have opened new doors for precise and successful treatments in fields ranging from oncology and autoimmune disorders to infectious and inflammatory diseases. This industry is booming in this era of precision medicine, with ongoing innovation, new applications, and a bright future.
| Report Attributes | Details |
|---|---|
| Monoclonal Antibodies Market Size (2022A) | US$ 205 Billion |
| Estimated Market Value (2023E) | US$ 228.99 Billion |
| Forecasted Market Value (2033F) | US$ 692.39 Billion |
| Global Market Growth Rate (2023 to 2033) | 11.7% CAGR |
| Asia Pacific Market Growth Rate (2023 to 2033) | 12.3% CAGR |
| North America Market Share (2022) | 47.2% |
| Human Source Segment Share (2022) | 52.5% |
| Humanized Source Segment Growth Rate (2023 to 2033) | 11.2% CAGR |
| In Vitro Production Segment Share (2022) | 76.2% |
| Hospital Segment Share (2022) | 40% |
| Key Companies Profiled | Novartis AG; Pfizer Inc.; GlaxoSmithKline PLC; Amgen Inc.; Merck &Co. Inc.; Daiichi Sankyo Company Ltd.; Abbott Laboratories; AstraZeneca PLC; Eli Lilly and Company; Johnson & Johnson Services Inc.; Bayer AG; Bristol Myers Squibb; F.Hoffman-La Roche Ltd.; Viatris Inc.; Biogen Inc.; Thermo Fischer Scientific Inc.; Novo Nordisk A/S; Sanofi SA; Merck KGaA; AbbVie |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
What is Shaping the Growth of the Monoclonal Antibodies Market?
“High Treatment Efficacy of Monoclonal Antibodies with Minimal Side Effects”
The unique ability of monoclonal antibodies to specifically target certain antigens or proteins with great affinity leads to exceptional therapy efficacy. Unlike standard medicines, which can have broad and often unwanted side effects, monoclonal antibodies target the specific cellular or molecular contributing factors that cause diseases. This focused approach is especially important in the treatment of diseases like cancer, where the goal is to destroy malignant cells while causing the least amount of harm to healthy tissues. The promise of effective therapies with few side effects has fueled the rapid adoption of monoclonal antibody drugs.
“Personalized Treatments Leading to Enhanced Therapeutic Outcomes”
Monoclonal antibodies enable treatment to be tailored to each patient's unique genetic and molecular profile. This customization of medicines to a patient's individual needs not only improves therapy outcomes but also aligns with precision medicine ideals. Patients, particularly those with chronic and life-threatening disorders, benefit from monoclonal antibodies that take genetic variants and individual disease presentations into account.
This personalization promotes a stronger bond between healthcare practitioners and patients by addressing their specific needs, ultimately leading to higher treatment adherence and patient satisfaction. The patient-centric approach, along with the precise and focused nature of monoclonal antibodies, has become a beacon of hope for individuals seeking highly effective, individualized treatment alternatives, cementing their key role in the future of healthcare.
What Can Hinder the Uptake of Monoclonal Antibodies?
“Risk of Development of Anti-monoclonal Antibodies against Therapeutic Monoclonal Antibodies”
Immunogenicity can be a substantial hurdle in monoclonal antibody therapy, especially when the immune response neutralizes the desired therapeutic benefit. One of the key concerns of immunogenicity is that a patient's immune system may mistake monoclonal antibodies for foreign invaders, creating antibodies that can counteract the therapeutic effects of these molecules. This phenomenon varies between patients and is affected by several factors, including the specific monoclonal antibody, the patient's unique immune system, and the length of treatment.
In cancer, for example, when precision is essential, production of neutralizing antibodies may result in inadequate tumor targeting and therapy failure. Furthermore, development of immunogenicity can lead to adverse effects such as infusion-related hypersensitivity and, in rare situations, severe allergic reactions. These reactions not only raise safety issues, but they also necessitate further medical interventions, putting additional strain on healthcare systems and negatively impacting patient well-being. While monoclonal antibodies have transformed modern medicine, immunogenicity remains a severe barrier.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
How Can Start-ups Differentiate Themselves Amidst the Tough Competition?
“Emphasis on Enhancing Specificity of Monoclonal Antibodies for Improved Patient Outcome”
Start-ups must concentrate on developing novel technologies, platforms, or techniques that can improve monoclonal antibody production efficiency, specificity, or therapy outcomes. Collaborations with existing pharmaceutical or biotechnology companies can provide start-ups with access to critical resources, knowledge, and distribution channels, allowing them to develop their operations more quickly.
Investigating niche monoclonal antibody applications, particularly in uncommon diseases or new industries, provides an opportunity to differentiate and potentially become leaders in those specialized segments, which may be less congested and more open to novel ideas. Regulatory compliance is non-negotiable for monoclonal antibody manufacturers. Thus, start-ups should ensure that they meet the severe regulatory criteria that regulate the monoclonal antibody business.
Country-wise Insights
North America held a leading market share of 47.2% in 2022. From 2023 to 2033, the Asia Pacific market is forecasted to expand at a CAGR of 12.3%.
How is the United States Contributing to the Expansion of the Market?
“Favorable Healthcare Investment Climate and Supportive Regulatory System”
The United States has a powerful healthcare system and a strong presence of pharmaceutical and biotechnology businesses at the forefront of monoclonal antibody development. This encourages innovation and research, resulting in a steady influx of ground-breaking cures.
The country benefits from a supportive regulatory system that expedites monoclonal antibody approval, recognizing their potential to meet unmet medical needs. The expanding elderly population in the United States population and changing disease patterns, exemplified by an increase in the frequency of chronic diseases such as cancer and autoimmune disorders, feed the desire for precise and focused treatments, which necessitates the adoption of monoclonal antibodies.
- According to the American Cancer Society, more than 1.8 million new cancer cases were reported in 2020, with 606,520 deaths.
How are the Markets in India and China Progressing?
“Heavy Healthcare Infrastructure Investment and Low Production Costs”
India and China play a crucial role in driving the monoclonal antibodies market growth. These countries have a large and growing affluent population, which drives up demand for modern healthcare solutions. As the prevalence of chronic diseases such as cancer and autoimmune diseases rises in these areas, monoclonal antibodies represent a viable route for precise and successful treatment.
Both India and China have invested heavily in their healthcare infrastructure, research capacities, and pharmaceutical sectors in recent years. As a result, the biotechnology sector is thriving, with a rising emphasis on monoclonal antibody production. The low cost of production and research in these nations has attracted worldwide pharmaceutical corporations, resulting in cooperation and investments in monoclonal antibody development.
- According to the World Health Organization, in 2020, approximately 10 million people died due to cancer worldwide.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Insights
The human source segment held 52.5% of the market in 2022. Over the forecast period, the humanized source type is anticipated to rise at a CAGR of 11.2%. The in vitro production segment held a market share of 76.2% in 2022. The hospitals segment by end-use held 40% of monoclonal antibodies market share and generated US$ 79 billion in sales in 2022.
What is the Growth Outlook for the Indication Segment?
“Increasing Demand for Monoclonal Antibody Therapeutics for Autoimmune Diseases”
Millions of individuals worldwide suffer from autoimmune illnesses, which are caused by the immune system wrongly attacking the body's cells and tissues, and the need for effective therapies has never been greater. Monoclonal antibodies are the treatment option for a variety of autoimmune illnesses, including rheumatoid arthritis, multiple sclerosis, and Crohn's disease.
The ability of monoclonal antibodies to control the immune system is one of the primary aspects contributing to the prominence of the segment. These biologics can target specific molecules and pathways involved in the autoimmune response, decreasing inflammation and disease development. This focused strategy is not only highly successful, but it also reduces the risk of systemic side effects associated with traditional treatments such as corticosteroids and immunosuppressants.
Monoclonal antibodies have proven to be effective in establishing and maintaining illness remission, significantly increasing the quality of life for autoimmune condition patients. As a result, demand for monoclonal antibody therapeutics in the category of autoimmune illnesses has increased, creating a significant market potential for pharmaceutical and biotechnology businesses.
Competitive Landscape
Presence of multiple significant competitors at the forefront of biopharmaceutical innovation characterizes the competitive landscape of the monoclonal antibodies market. These firms have established themselves as market leaders in the top antibody discovery companies and commercialization of monoclonal antibody therapeutics, providing a diverse range of therapy choices in a variety of therapeutic areas.
Roche Holdings, Regeneron Pharmaceuticals, Johnson & Johnson, Bristol-Myers Squibb, and AstraZeneca, are among the top companies in the monoclonal antibody market, each bringing their unique strengths and contributions to the world of monoclonal antibodies, touching on areas such as autoimmune diseases, immuno-oncology, gastroenterology, and more.
A competitive environment encourages innovation, resulting in a steady stream of new and improved monoclonal antibody therapeutics that broaden treatment options, improve patient care, and, ultimately, drive the evolution of modern healthcare.
- Bristol-Myers Squibb Company gained FDA clearance in November 2021 for Opdivo (nivolumab) + Yervoy (ipilimumab) coupled with restricted chemotherapy as first-line treatment of metastatic or recurrent non-small cell lung cancer.
Segmentation of Monoclonal Antibodies Market Research
-
By Production :
- In Vivo
- In Vitro
-
By Source :
- Murine
- Chimeric
- Humanized
- Human
- Others
-
By Indication :
- Cancer
- Autoimmune Diseases
- Inflammatory Diseases
- Infectious Diseases
- Others
-
By End User :
- Hospitals
- Specialty Centers
- Research Institutes
- Others
-
By Region :
- North America
- Europe
- Latin America
- East Asia
- South Asia & Oceania
- Middle East & Africa
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Market Background
- 4. Global Market Pricing Analysis
- 5. Global Market Analysis (2018 to 2022) and Forecast (2023 to 2033)
- 6. Global Market Analysis (2018 to 2022) and Forecast (2023 to 2033), by Production
- 6.1. In Vivo
- 6.2. In Vitro
- 7. Global Market Analysis (2018 to 2022) and Forecast (2023 to 2033), by Source
- 7.1. Murine
- 7.2. Chimeric
- 7.3. Humanized
- 7.4. Human
- 7.5. Others
- 8. Global Market Analysis (2018 to 2022) and Forecast (2023 to 2033), by Indication
- 8.1. Cancer
- 8.2. Autoimmune Diseases
- 8.3. Inflammatory Diseases
- 8.4. Infectious Diseases
- 8.5. Others
- 9. Global Market Analysis (2018 to 2022) and Forecast (2023 to 2033), by End User
- 9.1. Hospitals
- 9.2. Specialty Centers
- 9.3. Research Institutes
- 9.4. Others
- 10. Global Market Analysis (2018 to 2022) and Forecast (2023 to 2033), by Region
- 10.1. North America
- 10.2. Europe
- 10.3. East Asia
- 10.4. South Asia
- 10.5. Latin America
- 10.6. Middle East & Africa (MEA)
- 10.7. Oceania
- 11. North America Market Analysis and Forecast
- 12. Europe Market Analysis and Forecast
- 13. East Asia Market Analysis and Forecast
- 14. South Asia Market Analysis and Forecast
- 15. Latin America Market Analysis and Forecast
- 16. Middle East & Africa Market Analysis and Forecast
- 17. Oceania Market Analysis and Forecast
- 18. Global Market Analysis Key Countries
- 19. Competition Landscape
- 20. Competition Analysis
- 20.1. Novartis AG
- 20.2. Pfizer Inc.
- 20.3. GlaxoSmithKline PLC
- 20.4. Amgen Inc.
- 20.5. Merck & Co. Inc.
- 20.6. Daiichi Sankyo Company Ltd.
- 20.7. Abbott Laboratories
- 20.8. AstraZeneca PLC
- 20.9. Eli Lilly and Company
- 20.10. Johnson & Johnson Services Inc.
- 20.11. Bayer AG
- 20.12. Bristol Myers Squibb
- 20.13. F. Hoffman-La Roche Ltd.
- 20.14. Viatris Inc.
- 20.15. Biogen Inc.
- 20.16. Thermo Fisher Scientific Inc.
- 20.17. Novo Nordisk A/S
- 20.18. Sanofi SA
- 20.19. Merck KGaA
- 20.20. AbbVie
- 21. Appendix
- 22. Definitions of Analytical Frameworks
- 23. Sources and References
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market by Production, 2018 to 2033
Table 02: Global Market Value (US$ Mn), by Production, 2018 to 2033
Table 03: Global Market by Source, 2018 to 2033
Table 04: Global Market Value (US$ Mn), by Source, 2018 to 2033
Table 05: Global Market by Indication, 2018 to 2033
Table 06: Global Market Value (US$ Mn), by Indication, 2018 to 2033
Table 07: Global Market by End Userr, 2018 to 2033
Table 08: Global Market Value (US$ Mn), by End Userr, 2018 to 2033
Table 09: Global Market by Region, 2018 to 2033
Table 10: Global Market Value (US$ Mn), by Region, 2018 to 2033
Table 11: North America Market by Production, 2018 to 2033
Table 12: North America Market Value (US$ Mn), by Production, 2018 to 2033
Table 13: North America Market by Source, 2018 to 2033
Table 14: North America Market Value (US$ Mn), by Source, 2018 to 2033
Table 15: North America Market by Indication, 2018 to 2033
Table 16: North America Market Value (US$ Mn), by Indication, 2018 to 2033
Table 17: North America Market by End Userr, 2018 to 2033
Table 18: North America Market Value (US$ Mn), by End Userr, 2018 to 2033
Table 19: North America Market by Country, 2018 to 2033
Table 20: North America Market Value (US$ Mn), by Country, 2018 to 2033
Table 21: Europe Market by Production, 2018 to 2033
Table 22: Europe Market Value (US$ Mn), by Production, 2018 to 2033
Table 23: Europe Market by Source, 2018 to 2033
Table 24: Europe Market Value (US$ Mn), by Source, 2018 to 2033
Table 25: Europe Market by Indication, 2018 to 2033
Table 26: Europe Market Value (US$ Mn), by Indication, 2018 to 2033
Table 27: Europe Market by End Userr, 2018 to 2033
Table 28: Europe Market Value (US$ Mn), by End Userr, 2018 to 2033
Table 29: Europe Market by Country, 2018 to 2033
Table 30: Europe Market Value (US$ Mn), by Country, 2018 to 2033
Table 31: East Asia Market by Production, 2018 to 2033
Table 32: East Asia Market Value (US$ Mn), by Production, 2018 to 2033
Table 33: East Asia Market by Source, 2018 to 2033
Table 34: East Asia Market Value (US$ Mn), by Source, 2018 to 2033
Table 35: East Asia Market by Indication, 2018 to 2033
Table 36: East Asia Market Value (US$ Mn), by Indication, 2018 to 2033
Table 37: East Asia Market by End Userr, 2018 to 2033
Table 38: East Asia Market Value (US$ Mn), by End Userr, 2018 to 2033
Table 39: East Asia Market by Country, 2018 to 2033
Table 40: East Asia Market Value (US$ Mn), by Country, 2018 to 2033
Table 41: South Asia Market by Production, 2018 to 2033
Table 42: South Asia Market Value (US$ Mn), by Production, 2018 to 2033
Table 43: South Asia Market by Source, 2018 to 2033
Table 44: South Asia Market Value (US$ Mn), by Source, 2018 to 2033
Table 45: South Asia Market by Indication, 2018 to 2033
Table 46: South Asia Market Value (US$ Mn), by Indication, 2018 to 2033
Table 47: South Asia Market by End Userr, 2018 to 2033
Table 48: South Asia Market Value (US$ Mn), by End Userr, 2018 to 2033
Table 49: South Asia Market by Country, 2018 to 2033
Table 50: South Asia Market Value (US$ Mn), by Country, 2018 to 2033
Table 51: Latin America Market by Production, 2018 to 2033
Table 52: Latin America Market Value (US$ Mn), by Production, 2018 to 2033
Table 53: Latin America Market by Source, 2018 to 2033
Table 54: Latin America Market Value (US$ Mn), by Source, 2018 to 2033
Table 55: Latin America Market by Indication, 2018 to 2033
Table 56: Latin America Market Value (US$ Mn), by Indication, 2018 to 2033
Table 57: Latin America Market by End Userr, 2018 to 2033
Table 58: Latin America Market Value (US$ Mn), by End Userr, 2018 to 2033
Table 59: Latin America Market by Country, 2018 to 2033
Table 60: Latin America Market Value (US$ Mn), by Country, 2018 to 2033
Table 61: Middle East and Africa Market by Production, 2018 to 2033
Table 62: Middle East and Africa Market Value (US$ Mn), by Production, 2018 to 2033
Table 63: Middle East and Africa Market by Source, 2018 to 2033
Table 64: Middle East and Africa Market Value (US$ Mn), by Source, 2018 to 2033
Table 65: Middle East and Africa Market by Indication, 2018 to 2033
Table 66: Middle East and Africa Market Value (US$ Mn), by Indication, 2018 to 2033
Table 67: Middle East and Africa Market by End Userr, 2018 to 2033
Table 68: Middle East and Africa Market Value (US$ Mn), by End Userr, 2018 to 2033
Table 69: Middle East and Africa Market by Country, 2018 to 2033
Table 70: Middle East and Africa Market Value (US$ Mn), by Country, 2018 to 2033
Table 71: Oceania Market by Production, 2018 to 2033
Table 72: Oceania Market Value (US$ Mn), by Production, 2018 to 2033
Table 73: Oceania Market by Source, 2018 to 2033
Table 74: Oceania Market Value (US$ Mn), by Source, 2018 to 2033
Table 75: Oceania Market by Indication, 2018 to 2033
Table 76: Oceania Market Value (US$ Mn), by Indication, 2018 to 2033
Table 77: Oceania Market by End Userr, 2018 to 2033
Table 78: Oceania Market Value (US$ Mn), by End Userr, 2018 to 2033
Table 79: Oceania Market by Country, 2018 to 2033
Table 80: Oceania Market Value (US$ Mn), by Country, 2018 to 2033
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Fig 01: Global Market Value (US$) and Y-o-Y Growth, 2018 to 2033
Fig 02: Global Absolute $ Historical Market (2018 to 2022) and Absolute $ Opportunity (2023 to 2033), US$ Mn
Fig 03: Global Market Value Y-o-Y Growth and Forecast, 2018 to 2033
Fig 04: Global Market Incremental $ Opportunity (US$ Thousand), 2023 to 2033
Fig 05: Global Market Share, By Production – 2023 to 2033
Fig 06: Global Market Y-o-Y Growth Projections, By Production – 2023 to 2033
Fig 07: Global Market Attractiveness Index, By Production – 2023 to 2033
Fig 08: Global Market Share, By Source – 2023 to 2033
Fig 09: Global Market Y-o-Y Growth Projections, By Source – 2023 to 2033
Fig 10: Global Market Attractiveness Index, By Source – 2023 to 2033
Fig 11: Global Market Share, By Indication – 2023 to 2033
Fig 12: Global Market Y-o-Y Growth Projections, By Indication – 2023 to 2033
Fig 13: Global Market Attractiveness Index, By Indication – 2023 to 2033
Fig 14: Global Market Share, By End Userr – 2023 to 2033
Fig 15: Global Market Y-o-Y Growth Projections, By End Userr – 2023 to 2033
Fig 16: Global Market Attractiveness Index, By End Userr – 2023 to 2033
Fig 17: Global Market Share, by Region – 2023 to 2033
Fig 18: Global Market Y-o-Y Growth Projections, by Region – 2023 to 2033
Fig 19: Global Market Attractiveness Index, by Region – 2023 to 2033
Fig 20: Y-o-Y Growth Comparison of Market: North America Vs North America Countries Vs North America Average
Fig 21: North America Market Share, By Production – 2023 to 2033
Fig 22: North America Market Y-o-Y Growth Projections, By Production – 2023 to 2033
Fig 23: North America Market Attractiveness Index, By Production – 2023 to 2033
Fig 24: North America Market Share, By Source – 2023 to 2033
Fig 25: North America Market Y-o-Y Growth Projections, By Source – 2023 to 2033
Fig 26: North America Market Attractiveness Index, By Source – 2023 to 2033
Fig 27: North America Market Share, By Indication – 2023 to 2033
Fig 28: North America Market Y-o-Y Growth Projections, By Indication – 2023 to 2033
Fig 29: North America Market Attractiveness Index, By Indication – 2023 to 2033
Fig 30: North America Market Share, By End Userr – 2023 to 2033
Fig 31: North America Market Y-o-Y Growth Projections, By End Userr – 2023 to 2033
Fig 32: North America Market Attractiveness Index, By End Userr – 2023 to 2033
Fig 33: North America Market Share, By Country – 2023 to 2033
Fig 34: North America Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Fig 35: North America Market Attractiveness Index, By Country – 2023 to 2033
Fig 36: Y-o-Y Growth Comparison of Market: Europe Vs Europe Countries Vs Europe Average
Fig 37: Europe Market Share, By Production – 2023 to 2033
Fig 38: Europe Market Y-o-Y Growth Projections, By Production – 2023 to 2033
Fig 39: Europe Market Attractiveness Index, By Production – 2023 to 2033
Fig 40: Europe Market Share, By Source – 2023 to 2033
Fig 41: Europe Market Y-o-Y Growth Projections, By Source – 2023 to 2033
Fig 42: Europe Market Attractiveness Index, By Source – 2023 to 2033
Fig 43: Europe Market Share, By Indication – 2023 to 2033
Fig 44: Europe Market Y-o-Y Growth Projections, By Indication – 2023 to 2033
Fig 45: Europe Market Attractiveness Index, By Indication – 2023 to 2033
Fig 46: Europe Market Share, By End Userr – 2023 to 2033
Fig 47: Europe Market Y-o-Y Growth Projections, By End Userr – 2023 to 2033
Fig 48: Europe Market Attractiveness Index, By End Userr – 2023 to 2033
Fig 49: Europe Market Share, By Country – 2023 to 2033
Fig 50: Europe Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Fig 51: Europe Market Attractiveness Index, By Country – 2023 to 2033
Fig 52: Y-o-Y Growth Comparison of Market: East Asia Vs East Asia Countries Vs East Asia Average
Fig 53: East Asia Market Share, By Production – 2023 to 2033
Fig 54: East Asia Market Y-o-Y Growth Projections, By Production – 2023 to 2033
Fig 55: East Asia Market Attractiveness Index, By Production – 2023 to 2033
Fig 56: East Asia Market Share, By Source – 2023 to 2033
Fig 57: East Asia Market Y-o-Y Growth Projections, By Source – 2023 to 2033
Fig 58: East Asia Market Attractiveness Index, By Source – 2023 to 2033
Fig 59: East Asia Market Share, By Indication – 2023 to 2033
Fig 60: East Asia Market Y-o-Y Growth Projections, By Indication – 2023 to 2033
Fig 61: East Asia Market Attractiveness Index, By Indication – 2023 to 2033
Fig 62: East Asia Market Share, By End Userr – 2023 to 2033
Fig 63: East Asia Market Y-o-Y Growth Projections, By End Userr – 2023 to 2033
Fig 64: East Asia Market Attractiveness Index, By End Userr – 2023 to 2033
Fig 65: East Asia Market Share, By Country – 2023 to 2033
Fig 66: East Asia Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Fig 67: East Asia Market Attractiveness Index, By Country – 2023 to 2033
Fig 68: Y-o-Y Growth Comparison of Market: South Asia Vs South Asia Countries Vs South Asia Average
Fig 69: South Asia Market Share, By Production – 2023 to 2033
Fig 70: South Asia Market Y-o-Y Growth Projections, By Production – 2023 to 2033
Fig 71: South Asia Market Attractiveness Index, By Production – 2023 to 2033
Fig 72: South Asia Market Share, By Source – 2023 to 2033
Fig 73: South Asia Market Y-o-Y Growth Projections, By Source – 2023 to 2033
Fig 74: South Asia Market Attractiveness Index, By Source – 2023 to 2033
Fig 75: South Asia Market Share, By Indication – 2023 to 2033
Fig 76: South Asia Market Y-o-Y Growth Projections, By Indication – 2023 to 2033
Fig 77: South Asia Market Attractiveness Index, By Indication – 2023 to 2033
Fig 78: South Asia Market Share, By End Userr – 2023 to 2033
Fig 78: South Asia Market Y-o-Y Growth Projections, By End Userr – 2023 to 2033
Fig 80: South Asia Market Attractiveness Index, By End Userr – 2023 to 2033
Fig 81: South Asia Market Share, By Country – 2023 to 2033
Fig 82: South Asia Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Fig 83: South Asia Market Attractiveness Index, By Country – 2023 to 2033
Fig 84: Y-o-Y Growth Comparison of Market: Latin America Vs Latin America Countries Vs Latin America Average
Fig 85: Latin America Market Share, By Production – 2023 to 2033
Fig 86: Latin America Market Y-o-Y Growth Projections, By Production – 2023 to 2033
Fig 87: Latin America Market Attractiveness Index, By Production – 2023 to 2033
Fig 88: Latin America Market Share, By Source – 2023 to 2033
Fig 89: Latin America Market Y-o-Y Growth Projections, By Source – 2023 to 2033
Fig 90: Latin America Market Attractiveness Index, By Source – 2023 to 2033
Fig 91: Latin America Market Share, By Indication – 2023 to 2033
Fig 92: Latin America Market Y-o-Y Growth Projections, By Indication – 2023 to 2033
Fig 93: Latin America Market Attractiveness Index, By Indication – 2023 to 2033
Fig 94: Latin America Market Share, By End Userr – 2023 to 2033
Fig 95: Latin America Market Y-o-Y Growth Projections, By End Userr – 2023 to 2033
Fig 96: Latin America Market Attractiveness Index, By End Userr – 2023 to 2033
Fig 97: Latin America Market Share, By Country – 2023 to 2033
Fig 98: Latin America Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Fig 99: Latin America Market Attractiveness Index, By Country – 2023 to 2033
Fig 100: Y-o-Y Growth Comparison of Market: MEA Vs MEA Countries Vs MEA Average
Fig 101: MEA Market Share, By Production – 2023 to 2033
Fig 102: MEA Market Y-o-Y Growth Projections, By Production – 2023 to 2033
Fig 103: MEA Market Attractiveness Index, By Production – 2023 to 2033
Fig 104: MEA Market Share, By Source – 2023 to 2033
Fig 105: MEA Market Y-o-Y Growth Projections, By Source – 2023 to 2033
Fig 106: MEA Market Attractiveness Index, By Source – 2023 to 2033
Fig 107: MEA Market Share, By Indication – 2023 to 2033
Fig 108: MEA Market Y-o-Y Growth Projections, By Indication – 2023 to 2033
Fig 109: MEA Market Attractiveness Index, By Indication – 2023 to 2033
Fig 110: MEA Market Share, By End Userr – 2023 to 2033
Fig 111: MEA Market Y-o-Y Growth Projections, By End Userr – 2023 to 2033
Fig 112: MEA Market Attractiveness Index, By End Userr – 2023 to 2033
Fig 113: MEA Market Share, By Country – 2023 to 2033
Fig 114: MEA Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Fig 115: MEA Market Attractiveness Index, By Country – 2023 to 2033
Fig 116: Y-o-Y Growth Comparison of Market: Oceania Vs Oceania Countries Vs Oceania Average
Fig 117: Oceania Market Share, By Production – 2023 to 2033
Fig 118: Oceania Market Y-o-Y Growth Projections, By Production – 2023 to 2033
Fig 119: Oceania Market Attractiveness Index, By Production – 2023 to 2033
Fig 120: Oceania Market Share, By Source – 2023 to 2033
Fig 121: Oceania Market Y-o-Y Growth Projections, By Source – 2023 to 2033
Fig 122: Oceania Market Attractiveness Index, By Source – 2023 to 2033
Fig 123: Oceania Market Share, By Indication – 2023 to 2033
Fig 124: Oceania Market Y-o-Y Growth Projections, By Indication – 2023 to 2033
Fig 125: Oceania Market Attractiveness Index, By Indication – 2023 to 2033
Fig 126: Oceania Market Share, By End Userr – 2023 to 2033
Fig 127: Oceania Market Y-o-Y Growth Projections, By End Userr – 2023 to 2033
Fig 128: Oceania Market Attractiveness Index, By End Userr – 2023 to 2033
Fig 129: Oceania Market Share, By Country – 2023 to 2033
Fig 130: Oceania Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Fig 131: Oceania Market Attractiveness Index, By Country – 2023 to 2033
Fig 132: United States Market share by Production, 2022
Fig 133: United States Market share by Source, 2022
Fig 134: United States Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 135: United States Market Share by End Userr, 2022
Fig 136: Canada Market share by Production, 2022
Fig 137: Canada Market share by Source, 2022
Fig 138: Canada Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 139: Canada Market Share by End Userr, 2022
Fig 140: Germany Market share by Production, 2022
Fig 141: Germany Market share by Source, 2022
Fig 142: Germany Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 143: Germany Market Share by End Userr, 2022
Fig 144: United Kingdom Market share by Production, 2022
Fig 145: United Kingdom Market share by Source, 2022
Fig 146: United Kingdom Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 147: United Kingdom Market Share by End Userr, 2022
Fig 148: France Market share by Production, 2022
Fig 149: France Market share by Source, 2022
Fig 150: France Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 151: France Market Share by End Userr, 2022
Fig 152: Russia Market share by Production, 2022
Fig 153: Russia Market share by Source, 2022
Fig 154: Russia Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 155: Russia Market Share by End Userr, 2022
Fig 156: Spain Market share by Production, 2022
Fig 157: Spain Market share by Source, 2022
Fig 158: Spain Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 159: Spain Market Share by End Userr, 2022
Fig 160: Italy Market share by Production, 2022
Fig 161: Italy Market share by Source, 2022
Fig 162: Italy Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 163: Italy Market Share by End Userr, 2022
Fig 164: China Market share by Production, 2022
Fig 165: China Market share by Source, 2022
Fig 166: China Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 167: China Market Share by End Userr, 2022
Fig 168: Japan Market share by Production, 2022
Fig 169: Japan Market share by Source, 2022
Fig 170: Japan Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 171: Japan Market Share by End Userr, 2022
Fig 172: South Korea Market share by Production, 2022
Fig 173: South Korea Market share by Source, 2022
Fig 174: South Korea Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 175: South Korea Market Share by End Userr, 2022
Fig 176: India Market share by Production, 2022
Fig 177: India Market share by Source, 2022
Fig 178: India Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 179: India Market Share by End Userr, 2022
Fig 180: Singapore Market share by Production, 2022
Fig 181: Singapore Market share by Source, 2022
Fig 182: Singapore Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 183: Singapore Market Share by End Userr, 2022
Fig 184: Indonesia Market share by Production, 2022
Fig 185: Indonesia Market share by Source, 2022
Fig 186: Indonesia Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 187: Indonesia Market Share by End Userr, 2022
Fig 188: Thailand Market share by Production, 2022
Fig 189: Thailand Market share by Source, 2022
Fig 190: Thailand Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 191: Thailand Market Share by End Userr, 2022
Fig 192: Brazil Market share by Production, 2022
Fig 193: Brazil Market share by Source, 2022
Fig 194: Brazil Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 195: Brazil Market Share by End Userr, 2022
Fig 196: Mexico Market share by Production, 2022
Fig 197: Mexico Market share by Source, 2022
Fig 198: Mexico Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 199: Mexico Market Share by End Userr, 2022
Fig 200: Turkey Market share by Production, 2022
Fig 201: Turkey Market share by Source, 2022
Fig 202: Turkey Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 203: Turkey Market Share by End Userr, 2022
Fig 204: GCC Countries Market share by Production, 2022
Fig 205: GCC Countries Market share by Source, 2022
Fig 206: GCC Countries Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 207: GCC Countries Market Share by End Userr, 2022
Fig 208: South Africa Market share by Production, 2022
Fig 209: South Africa Market share by Source, 2022
Fig 210: South Africa Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 211: South Africa Market Share by End Userr, 2022
Fig 212: Australia Market share by Production, 2022
Fig 213: Australia Market share by Source, 2022
Fig 214: Australia Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 215: Australia Market Share by End Userr, 2022
Fig 216: New Zealand Market share by Production, 2022
Fig 217: New Zealand Market share by Source, 2022
Fig 218: New Zealand Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 219: New Zealand Market Share by End Userr, 2022
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
Which segment of the monoclonal antibodies market held a leading share in 2022?
Based on end use, hospitals held 40% share of the global monoclonal antibodies market in 2022.
How big is the monoclonal antibody market in 2023?
The monoclonal antibodies market value stands at US$ 228.99 billion in 2023.
What is the demand forecast for monoclonal antibodies?
Demand for monoclonal antibodies is forecasted to reach a market value of US$ 692.39 billion by 2033-end.
What is the sales growth projection for monoclonal antibodies?
Sales of monoclonal antibodies are projected to rise at a CAGR of 11.7% through 2033.
At what rate is the Asia Pacific market predicted to grow?
The Asia Pacific market is forecasted to expand at a CAGR of 12.3% over the forecast period.
Monoclonal Antibodies Market